Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Thirteen and twenty-six weeks ended December 2, 2006 (Fiscal 2007).
Business Overview: AngioDynamics designs, develops, manufactures, and markets medical devices for the minimally invasive treatment of peripheral vascular disease (PVD) and other non-coronary diseases. The company operates in a single segment focused on peripheral vascular disease.
Key Financial Metrics
| Metric (in thousands) | 13 Weeks Ended Dec 2, 2006 |
26 Weeks Ended Dec 2, 2006 |
26 Weeks Ended Nov 26, 2005 |
|---|---|---|---|
| Net Sales | $24,369 | $44,634 | $35,074 |
| Gross Profit | $14,244 | $26,170 | $20,366 |
| Gross Margin % | 58.5% | 58.6% | 58.1% |
| Operating Profit | $3,004 | $4,827 | $4,312 |
| Net Income | $2,454 | $4,353 | $2,948 |
| Diluted EPS | $0.15 | $0.27 | $0.23 |
| Cash from Operations | N/A | $5,018 | $2,381 |
| Cash & Equivalents (Balance Sheet) | $73,158 (as of Dec 2, 2006) | ||
| Total Debt | $2,845 (Current: $180; Long-term: $2,665) |
Note: All financial figures are in thousands, except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 30.3% ($5.7 million) for the quarter and 27.4% ($9.6 million) for the six-month period compared to the prior year. Growth was driven by new product introductions (Total Abscession drainage catheter, VenaCure procedure kit, Morpheus CT PICC) and market share gains.
- Profitability: Net income rose 48.3% for the quarter and 47.7% for the six-month period. Gross margin improved slightly to 58.6% due to a favorable product mix.
- Operating Expenses: Selling and marketing expenses increased 28.6% (quarter) and 27.7% (six months) due to expanded sales territories and commissions. General and administrative expenses surged 71.4% (quarter) and 73.5% (six months), driven by personnel increases, legal fees, and costs related to acquisition activities.
- Stock-Based Compensation: The company adopted SFAS 123(R) on June 4, 2006. Stock-based compensation expense recognized for the six months ended Dec 2, 2006, was $1.4 million, compared to negligible amounts in the prior year under the previous accounting method.
- Investment Income: Other income increased significantly due to higher interest income from a larger investment portfolio and higher yields.
Guidance, Outlook, Risks, and Unusual Items
Acquisitions and Strategic Outlook
- RITA Medical Systems, Inc.: On November 27, 2006, AngioDynamics entered into a merger agreement to acquire RITA for an anticipated total purchase price of approximately $220 million (stock and cash). Closing is subject to shareholder approval (scheduled for Jan 29, 2007) and regulatory clearance. A termination fee of $8 million is payable by RITA under certain circumstances.
- Oncobionic, Inc.: On October 12, 2006, the company agreed to acquire Oncobionic for a fixed price of $25 million (less debt) plus a 3% royalty on future sales of products using Oncobionic's technology. A $5 million non-refundable deposit was paid. Closing is contingent on successful human use tests for prostate cancer ablation.
Liquidity and Capital Resources
- The company holds $87.9 million in cash, cash equivalents, and marketable securities (59% of total assets).
- A $7.5 million line of credit expired in November 2006 and was not renewed.
- In December 2006, the company closed on $5 million in taxable adjustable rate notes to finance a facility expansion, hedged with an interest rate swap.
- Management anticipates current cash and operating cash flow will meet needs for the next 12 months, though additional financing may be required for future acquisitions.
Risks and Contingencies
- Litigation: The company is a defendant in patent infringement suits filed by Diomed, Inc. (trial set for March 12, 2007) and VNUS Medical Technologies, Inc. (trial set for October 2007). Potential loss in the Diomed case is estimated between $1.1 million and $10.5 million. The company disputes the claims and is seeking indemnification from its supplier, biolitec, though biolitec has not agreed to cover VNUS defense costs.
- Acquisition Risks: Integration challenges, diversion of management attention, and potential failure to realize anticipated synergies from the RITA and Oncobionic acquisitions.
- Stockholder Lawsuit: A class action lawsuit was filed against RITA and its directors challenging the proposed acquisition, which could delay or prevent the merger.
Investor Verification Checklist
- Acquisition Closing: Verify the status of shareholder approvals for the RITA and Oncobionic acquisitions scheduled for January 2007.
- Litigation Exposure: Monitor the outcome of the Diomed and VNUS patent infringement trials scheduled for 2007 and the status of indemnification negotiations with biolitec.
- Cash Position: Confirm the impact of the $5 million Oncobionic deposit and potential cash outflows for the RITA acquisition on liquidity.
- Product Performance: Validate continued sales growth of key new products (Total Abscession, VenaCure, Morpheus CT PICC) to sustain margin improvements.
- Accounting Impact: Review the ongoing impact of SFAS 123(R) adoption on future earnings and stock-based compensation expenses.